ATE275127T1 - Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems - Google Patents

Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems

Info

Publication number
ATE275127T1
ATE275127T1 AT00921148T AT00921148T ATE275127T1 AT E275127 T1 ATE275127 T1 AT E275127T1 AT 00921148 T AT00921148 T AT 00921148T AT 00921148 T AT00921148 T AT 00921148T AT E275127 T1 ATE275127 T1 AT E275127T1
Authority
AT
Austria
Prior art keywords
methods
compositions
acute
compounds
nervous system
Prior art date
Application number
AT00921148T
Other languages
English (en)
Inventor
Byoung Joo Gwag
Young Ae Lee
Bo Rum Ryu
Sung Hwa Yoon
Ho Sang Moon
Original Assignee
Neurotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotech Co Ltd filed Critical Neurotech Co Ltd
Application granted granted Critical
Publication of ATE275127T1 publication Critical patent/ATE275127T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00921148T 2000-04-19 2000-04-19 Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems ATE275127T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2000/000366 WO2001079153A1 (en) 2000-04-19 2000-04-19 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system

Publications (1)

Publication Number Publication Date
ATE275127T1 true ATE275127T1 (de) 2004-09-15

Family

ID=19198200

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921148T ATE275127T1 (de) 2000-04-19 2000-04-19 Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems

Country Status (10)

Country Link
EP (1) EP1274675B1 (de)
JP (1) JP3854154B2 (de)
CN (2) CN1267408C (de)
AT (1) ATE275127T1 (de)
AU (2) AU4149400A (de)
CA (2) CA2656216C (de)
DE (1) DE60013491T2 (de)
DK (1) DK1274675T3 (de)
ES (1) ES2226818T3 (de)
WO (1) WO2001079153A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE275127T1 (de) * 2000-04-19 2004-09-15 Neurotech Co Ltd Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems
ITMI20012573A1 (it) * 2001-12-06 2003-06-06 D B P Dev Biotechonologica L P Gli acilsalicilati:una nuova classe di induttori di risposta heat shock
JP4113957B2 (ja) * 2002-06-19 2008-07-09 アムコア ファーマ， インコーポレイテッド テトラフルオロベンジル誘導体及びこれを含有する急性及び退行性脳神経系疾患の予防及び治療用薬学的組成物
KR100522188B1 (ko) 2003-01-20 2005-10-18 주식회사 뉴로테크 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
JP5208369B2 (ja) * 2005-08-24 2013-06-12 ニューロテック ファーマシューティカルズ カンパニー リミテッド 神経細胞の死滅または神経機能の障害を治療するための薬学製剤及び併用療法
ES2690205T3 (es) 2006-04-13 2018-11-19 Neurotech Pharmaceuticals Co., Ltd. Composición farmacéutica para tratar o prevenir enfermedades inflamatorias
WO2007119984A1 (en) * 2006-04-13 2007-10-25 Neurotech Co., Ltd. Salicylic acid derivative compound and pharmaceutical composition containing them
KR101189751B1 (ko) * 2006-04-13 2012-10-10 주식회사 지엔티파마 세포 손상 및 염증 질환의 치료 또는 예방용 약학 조성물
KR100852962B1 (ko) 2007-11-12 2008-08-20 주식회사 뉴로테크 2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
KR101204108B1 (ko) * 2009-02-09 2012-11-22 주식회사 지엔티파마 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
LT2396081T (lt) 2009-02-16 2017-09-11 Nogra Pharma Limited Alkilamido junginiai ir jų panaudojimas
AU2013217933B2 (en) 2012-02-09 2017-11-30 Nogra Pharma Limited Methods of treating fibrosis
AU2013248397A1 (en) 2012-04-18 2014-10-02 Nogra Pharma Limited Methods of treating lactose intolerance
AU2020217884B2 (en) 2019-02-08 2025-02-20 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
JP7437073B2 (ja) * 2019-07-08 2024-02-22 ジーエヌティー ファーマ カンパニー， リミテッド ５－ベンジルアミノサリチル酸誘導体を含む化粧品組成物及びその局所使用方法
CN116392486A (zh) * 2023-05-29 2023-07-07 四川大学华西医院 一种防治缺血性脑卒中的药物组合物及其应用
WO2024248510A1 (ko) 2023-06-02 2024-12-05 주식회사 지엔티파마 안정성 및 용출률이 개선된 크리스데살라진 함유 약학 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7008623A (de) * 1969-06-25 1970-12-29
JPS6056130B2 (ja) * 1978-03-20 1985-12-09 久光製薬株式会社 新規なサリチル酸誘導体
DK117484A (da) * 1983-03-14 1984-09-15 Carpibem 1-(2-carbethoxy-4-benzalkylamido-phenoxy)-3-amino-2-propanoler og fremgangsmaade til fremstilling deraf samt forbindelsernes anvendelse som laegemidler
JPS60237041A (ja) * 1984-03-02 1985-11-25 Yamamoto Kagaku Kogyo Kk ３−プロピオニルサリチル酸誘導体の製造法
IT1196348B (it) * 1984-11-29 1988-11-16 Italfarmaco Spa Composti ad attivita'antiinfiammatoria
DE20321227U1 (de) * 1987-12-29 2006-12-07 Pliva Istrazivanje I Razvoj D.O.O. Isostrukturelle Pseudopolymorphe von 9-Deoxo-9a-Aza-9a-Methyl-9a-Homoerythromycin A
EP0675886B1 (de) * 1992-12-10 2000-07-05 Pfizer Inc. Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
ATE275127T1 (de) * 2000-04-19 2004-09-15 Neurotech Co Ltd Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems

Also Published As

Publication number Publication date
CA2405518C (en) 2009-07-07
CN1939895B (zh) 2010-05-12
JP2003535051A (ja) 2003-11-25
CA2656216A1 (en) 2001-10-25
CA2656216C (en) 2012-01-24
EP1274675B1 (de) 2004-09-01
CN1452610A (zh) 2003-10-29
AU4149400A (en) 2001-10-30
DE60013491T2 (de) 2005-09-01
JP3854154B2 (ja) 2006-12-06
ES2226818T3 (es) 2005-04-01
WO2001079153A1 (en) 2001-10-25
CN1939895A (zh) 2007-04-04
DE60013491D1 (de) 2004-10-07
AU2000241494B2 (en) 2005-03-17
CN1267408C (zh) 2006-08-02
EP1274675A1 (de) 2003-01-15
DK1274675T3 (da) 2004-12-06
CA2405518A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
DE60013491D1 (de) Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems
SI1663185T1 (sl) Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
GB0129260D0 (en) Pharmaceutical compositions and their uses
BR9709501A (pt) Composto, composição farmacêutica , e, processos para tratar ou prevenir a esquizofrrenia e para sintetizar um composto
EP0593658A4 (de) Zusammensetzungen und verfahren zur hemmung der leukozytenadhäsion an zns-myelin.
GEP20084420B (en) Use of imidazole compounds for the treatment of neurodegenerative disorders
IL144144A0 (en) Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
ATE409490T1 (de) Nahrungszusammensetzungen und verfahren zur behandlung oder vorbeugung von osteoporose
PL347469A1 (en) Use of certain drugs for treating nerve root injury
ATE415963T1 (de) Zusammensetzungen aus dmxaa und anderen antikrebsmittel
WO2002072542A3 (en) Ph-dependent nmda receptor antagonists
ATE235244T1 (de) Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
HU9501146D0 (en) 2-amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and/or kynurenine-3-hydroxylase inhibiting activity
EP1032556A4 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
DE60218837D1 (de) Verbindungen und verfahren zur hemmung des achselgeruches
TW200628473A (en) Novel heterocycles
BR0008603A (pt) Método para tratamento de copd
DE69406430D1 (de) Alkaloide von Mappie foetida, deren Anwendung und diese enthaltende Zusammensetzungen
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
MXPA04000805A (es) Peptidos que tienen actividad antiangiogenica.
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
GR3034661T3 (en) Use of Selegiline in vetenary medicine.
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
MX9804577A (es) Composiciones que contienen bismuto y uno o mas antimicrobianos, para la prevencion y tratamiento de trastornos gastrointestinales.
MX9804576A (es) Composiciones que contienen bismuto, para la prevencion y tratamiento de trastornos gastrointestinales.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties